Novogen, The Future of Cancer Therapy, Releases Jun 2017 Newsletter

Novogen (ASX: NRT) is an Australian oncology-focused biotechnology company that is pleased to present the company’s June 2017 Newsletter.

KEY TAKEAWAYS:

In April, Novogen planned phase II clinical trial in relation to the most common and aggressive form of primary brain cancer. Novogen plans to focus the study on the almost two-thirds of patients.
- Approximately 200 patients will be recruited, and the company aims to start the study in the second half of calendar 2017.
The study will be a randomised controlled trial and, if it is successful, it may offer an opportunity to approach FDA, the US regulatory agency, to discuss accelerated approval without waiting for a full phase III study.
Phase I study of Cantrixil in ovarian cancer is progressing well. Five of the six participating hospitals are now open to recruitment. The timing of initial data is difficult to predict, because the design entails increasing doses until patients start to experience side effects, and this cannot be accurately predicted in advance.
Novogen’s decision during April to terminate the development of Anisina, the lead program from the company’s anti-tropomyosin research. Despite the great work that has been done with Anisina, the emerging data did not, in our view, make it a promising candidate to take forward into human trials.
In closing, the Novogen team remains tightly focused on delivering its programs.